VKTX — Viking Therapeutics Share Price
0.000.00%
Last trade - 00:00- $6.99bn
- $6.63bn
- 55
- 22
- 80
- 51
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 20.06 | ||
| Price to Tang. Book | 20.06 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.86% | ||
| Return on Equity | -34.79% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.
Directors
- Lawson Macartney NEC (63)
- Brian Lian PRE (55)
- Greg Zante CFO (50)
- Marianne Mancini COO (56)
- Matthew Foehr DRC (48)
- S. Kathy Rouan IND (58)
- Charles Rowland IND (62)
- J. Matthew Singleton IND (68)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 24th, 2012
- Public Since
- April 29th, 2015
- No. of Shareholders
- 8
- No. of Employees
- 27
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 110,217,994
- Address
- 9920 Pacific Heights Blvd, Suite 350, SAN DIEGO, 92121
- Web
- https://vikingtherapeutics.com/
- Phone
- +1 8587044660
- Contact
- Greg Zante
- Auditors
- Marcum LLP
Upcoming Events for VKTX
Q1 2024 Viking Therapeutics Inc Earnings Call
Viking Therapeutics Inc Annual Shareholders Meeting
Viking Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Viking Therapeutics Inc Earnings Release
Similar to VKTX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Viking Therapeutics share price?
As of Today at 19:24 UTC, shares in Viking Therapeutics are trading at $63.42. This share price information is delayed by 15 minutes.
How has the Viking Therapeutics share price performed this year?
Shares in Viking Therapeutics last closed at $63.42 and the price had moved by +209.97% over the past 365 days. In terms of relative price strength the Viking Therapeutics share price has outperformed the S&P500 Index by +157.94% over the past year.
What are the analyst and broker recommendations for Viking Therapeutics?
The overall consensus recommendation for Viking Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Viking Therapeutics dividend yield?
Viking Therapeutics does not currently pay a dividend.
Does Viking Therapeutics pay a dividend?
Viking Therapeutics does not currently pay a dividend.
When does Viking Therapeutics next pay dividends?
Viking Therapeutics does not currently pay a dividend.
How do I buy Viking Therapeutics shares?
To buy shares in Viking Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Viking Therapeutics?
As of the previous close price of $63.42, shares in Viking Therapeutics had a market capitalisation of $6.99bn.
Where are Viking Therapeutics shares listed?
Here are the trading details for Viking Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VKTX
What kind of share is Viking Therapeutics?
Based on an overall assessment of its quality, value and momentum Viking Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Viking Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Viking Therapeutics is $113.80. That is 79.44% above the last closing price of $63.42.
Analysts covering Viking Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.12 for the next financial year.
What is the trend in the Viking Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Viking Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +436.81%.
As of the last closing price of $63.42, shares in Viking Therapeutics were trading +131.34% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Viking Therapeutics PE Ratio?
The Viking Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $63.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Viking Therapeutics?
Viking Therapeutics' management team is headed by:
- Lawson Macartney - NEC
- Brian Lian - PRE
- Greg Zante - CFO
- Marianne Mancini - COO
- Matthew Foehr - DRC
- S. Kathy Rouan - IND
- Charles Rowland - IND
- J. Matthew Singleton - IND